OMEROS CORP Restricted Cash and Investments, Noncurrent
OMEROS CORP (OMER) had Restricted Cash and Investments, Noncurrent of $1.15 million as of 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndInvestmentsNoncurrent · last filed 2019-03-01
- 2018-12-31: Restricted Cash and Investments, Noncurrent $1.15M.
- 2017-12-31: Restricted Cash and Investments, Noncurrent $5.83M.
- 2016-12-31: Restricted Cash and Investments, Noncurrent $5.83M.
- 2015-12-31: Restricted Cash and Investments, Noncurrent $10.68M.
| Period end | Restricted Cash and Investments, Noncurrent |
|---|---|
| 2018-12-31 | $1.15M 10-K · filed 2019-03-01 |
| 2017-12-31 | $5.83M 10-K · filed 2019-03-01 |
| 2016-12-31 | $5.83M 10-K · filed 2018-03-01 |
| 2015-12-31 | $10.68M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |